We also found that the pathologic responses were superior to the radiologic responses in pMMR/MSS CRC patients after the combined therapy, similar to the response to PD‐1 blockade in dMMR/MSI‐H CRC patients.24 Here, RPL17 is linked to colorectal carcinoma.